Suven Life Sciences has been granted patents by Canada, Japan and Korea for molecules which are developed as drugs, for the treatment of neuro-degenerative diseases. These molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need have huge market potential globally.
The granted patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease, Huntington’s disease, Parkinson and Schizophrenia, among others
Company Profile : Suven Life Sciences Ltd
Leave a Reply